Navigation Links
AIMSPRO is Awarded TGA Orphan Status for the Treatment of Amyotrophic Lateral Sclerosis

LONDON, June 1 /PRNewswire/ -- Privately owned UK biotech company Daval International Limited ( has been informed by Australia's Therapeutic Goods Administration (TGA) that its innovative anti-inflammatory agent AIMSPRO(R) has been awarded Orphan Status for the treatment of Amyotrophic Lateral Sclerosis (ALS).

ALS is the most common form of Motor Neuron Disease (MND), also known as Lou Gehrig's disease. AIMSPRO has already achieved TGA Orphan Status for the treatment of Krabbe Leukodystrophy (Krabbe's disease). Daval is now evaluating an international, multi-centre, placebo controlled, Randomised Clinical Trial to determine whether later stage ALS patients with poor respiratory function can be seen to benefit from the medication under double-blind conditions.

AIMSPRO is a new generation biological medicine which is sourced and manufactured in Australia. It is derived from hyperimmune caprine serum and is currently under Phase II trialling in Europe for advanced Scleroderma and for bladder dysfunction in Secondary Progressive Multiple Sclerosis. Both trials are expected to report in the first quarter of 2010. Additional open label experience with AIMSPRO, over an extended period, has led Daval to consider Proof of Concept studies in Adhesive Arachnoiditis, treatment resistant Myasthenia Gravis and Psoriatic arthritis.

AIMSPRO is listed on the Export Only section of the Australian Therapeutic Goods Registry and is imported into Europe by Biotec Distribution (Wales) Limited for clinical trial and "named patient use" purposes.

The veterinary form of the product, Ceremben(R) has shown efficacy, safety and tolerability in studies addressing critically important indications in standardbred and thoroughbred horses. The Australian regulator, the APVMA, has recently awarded Ceremben a Research Permit, which will enable confirmatory equine field trials to be rapidly completed. Ceremben is also being developed as a potential canine and feline anti-inflammatory agent.

SOURCE Daval International Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Ridge Diagnostics, Inc. Awarded Phase 2 National Science Foundation Grant
2. Global Health Research Foundation Awarded $25,000 Grant From Westly Foundation to Study Asthma in Californias Central Valley
3. KGI Professor Ian Phillips Awarded Defense Grants for Medical Combat Research
4. K-State Researchers Awarded Nearly $1 Million to Test Remedies, Investigate Link Between E. Coli and Distillers Grains
5. Modigene Awarded Israeli Government Grant to Support Development of Its Longer-Acting Interferon Beta
6. GeneGo is Awarded NCI Grant for Development of Systems Biology Platform for Integrative Data Analysis in Cancer
7. Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
8. Discovering How Video Games Can Motivate Healthy Behaviors: More than $2 Million Awarded to 12 Research Teams Across U.S.
9. TriLink Awarded a Phase II Grant for a Second Hot Start PCR Project
10. New Patent Awarded for Antigen-Sparing Vaccines that Elicit Robust Immunity
11. Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology
Post Your Comments:
(Date:12/1/2015)... -- Six months of adjunctive metformin therapy does not improve glycemic ... new research from T1D Exchange and funded by ... effect on measures of obesity, including weight and BMI. The ... of the American Medical Association , are from the largest ... overweight and obese adolescents with type 1 diabetes. ...
(Date:12/1/2015)... Russia has always been a country of choice for ... Europe in 2015 were tested in phase II-III ... has always been a country of choice for global multi-center phase ... in 2015 were tested in phase II-III clinical trials ... always been a country of choice for global multi-center phase III clinical ...
(Date:12/1/2015)... 1, 2015 Contraceptives ... Contraceptives, Male Condoms, Female Condoms, Intrauterine Devices, ... Diaphragms, Contraceptive Sponges, Non-Surgical Permanent Contraception Devices) ... Trends and Forecast 2014 - 2020 ", ... (TMR).The report states that the global contraceptives ...
Breaking Medicine Technology:
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... According ... of obesity groups has filed a discrimination claim against the U.S. Department of Health ... in their Affordable Care Act (ACA) plans are breaking the clause in the law ...
(Date:12/1/2015)... ... December 01, 2015 , ... Califia Farms , one of ... iconic bottle has won top honors in Beverage World Magazine’s Global Packaging Design Awards, ... that it has been selected as a 2015 U.S.A. Taste Champion in the American ...
(Date:12/1/2015)... MA (PRWEB) , ... December 01, 2015 , ... Growth ... in part due to decreases in utilization of hospital and nonhospital care, according to ... CompScope™ Medical Benchmarks for Louisiana, 16th Edition , found medical payments per claim ...
(Date:12/1/2015)... ... December 01, 2015 , ... CloudLIMS today ... Golden Bridge Business Awards under the New Products and Services category for its ... sample management software that helps labs organize data and track samples ...
(Date:12/1/2015)... New York, NY (PRWEB) , ... December 01, ... ... cause of non-traumatic limb amputations in the United States. Podiatrists are well aware ... (failure to adopt therapeutic behaviors) are often catastrophic contributors to diseases of the ...
Breaking Medicine News(10 mins):